Obstructive Hypertrophic Cardiomyopathy (oHCM) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Hypertrophic cardiomyopathy is a genetic disorder characterized by marked hypertrophy of the myocardium. It is frequently accompanied by dynamic left ventricular outflow tract obstruction and dyspnea, angina, and syncope symptoms. Obstructive Hypertrophic Cardiomyopathy (oHCM) is defined as HCM with left ventricular outflow tract obstruction causing a peak left ventricular outflow gradient of at least 30 mm Hg is observed in approximately 70% of patients with HCM frequently leads to symptoms including dyspnea, fatigue, chest pain, or syncope. The unique pathophysiology underlying the obstruction is its functional dynamic nature, greatly influenced by alterations in the load imposed on the left ventricle and its contractility. The block's initial therapy for symptomatic patients is medical therapy with β-blockers and calcium antagonists. However, a subset of patients have continued severe symptoms, which are unresponsive to medical treatment.

 

Hypertrophic cardiomyopathy (HCM) is a cardiac disorder affecting approximately 0.2–0.5% of the adult population, amongst which 50% to 70% of patients represent Obstructive Hypertrophic Cardiomyopathy (oHCM).

 

The competitive landscape of Obstructive Hypertrophic Cardiomyopathy (oHCM) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Obstructive Hypertrophic Cardiomyopathy (oHCM) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Obstructive Hypertrophic Cardiomyopathy (oHCM) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Obstructive Hypertrophic Cardiomyopathy (oHCM) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          mavacamten     MyoKardia, Inc. Phase 3

2          CK-3773274      Cytokinetics      Phase 2

3          Aficamten         Cytokinetics, Incorporated         Phase 2

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033